Malignant mediastinal tumor

1. Disease Description (Causes and Symptoms)

• Definition summary: Myeloproliferative neoplasms (MPNs) are a group of diseases in which clonal abnormalities of hematopoietic stem cells in the bone marrow cause excessive production of one or more of the red blood cell, white blood cell, or platelet lineages, or progression of bone marrow fibrosis. Representative disease types include polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), and chronic myeloid leukemia (CML).
• Main causes/pathophysiology:
  • Clonal proliferation of the hematopoietic system due to genetic mutations ( 주요 mutations: JAK2 V617F, CALR, MPL; in CML, the BCR‑ABL fusion gene).
  • Abnormal hematopoiesis in the bone marrow → increased cell counts in the peripheral blood (or extramedullary hematopoiesis and splenomegaly due to bone marrow fibrosis).
• Main symptoms:
  • Thrombosis (arterial or venous), bleeding tendency (due to platelet dysfunction or extreme thrombocytosis), splenomegaly (abdominal fullness or pain), anemia (fatigue or dizziness), facial flushing (particularly in PV), pruritus (particularly after exposure to heat), peripheral ischemia or pain (due to thrombosis or erythrocytosis), and easy bruising.
  • Some patients are asymptomatic and are found to have abnormal blood test results during a health screening.
• Risk of complications:
  • Thrombosis and bleeding, progression to myelofibrosis, and acute myeloid leukemia (incidence varies depending on the disease type and genetic mutation — for example, approximately 10–20%/10 years for PMF, 2–3%/10 years for PV, and <1%/10 years for ET have been reported).

2. Treatment Methods and Precautions

• Treatment goals: Prevent thrombosis and bleeding, relieve symptoms, suppress progression of complications (myelofibrosis and leukemia), and maintain quality of life
• Summary of treatment by disease type
  • Polycythemia vera (PV)
    • Standard: Control hematocrit — <45% for men and <42% for women are recommended.
    • Acute management: Control red blood cell volume through regular phlebotomy (e.g., 200–400 mL).
    • Thrombosis prevention: Low-dose aspirin (particularly in patients with cardiovascular risk factors or symptoms).
    • Cytoreductive therapy: For high-risk patients (age >60 years or a history of thrombosis), hydroxyurea (for chickenpox) is used first-line; interferon alpha may be considered for younger patients and during pregnancy.
    • JAK2 inhibitors (such as ruxolitinib): Used when there is intolerance or inadequate response to hydroxyurea.
    • Precaution: Iron supplementation is contraindicated when it may worsen erythrocytosis (excess iron can accelerate red blood cell production).
  • Essential thrombocythemia (ET)
    • Low-risk group (age <60, no history of thrombosis): Observation and low-dose aspirin if necessary (when there is a risk of thrombosis or microvascular symptoms).
    • High-risk group (age ≥60 or a history of thrombosis): Hydroxyurea first-line, interferon as an alternative (for younger patients or during pregnancy), and anagrelide as an adjunct for platelet control.
    • Precaution: With an extreme platelet count (e.g., >1 million), there is a risk of bleeding along with thrombosis due to platelet dysfunction.
  • Primary myelofibrosis (PMF)
    • Focus on symptom management: Transfusions, erythropoietin, corticosteroids, and other treatments for anemia; JAK inhibitors (ruxolitinib) for systemic symptoms and splenomegaly.
    • Definitive treatment: Allogeneic hematopoietic stem cell transplantation in patients of an appropriate age with appropriate indications (with therapeutic intent and the possibility of cure).
    • Management of complications (infection, bleeding, etc.) is necessary.
  • Chronic myeloid leukemia (CML)
    • Standard: BCR‑ABL-targeted therapy with tyrosine kinase inhibitors — imatinib, dasatinib, nilotinib, etc.
• Other treatment/management
  • When thrombosis occurs, anticoagulation and thrombolytic therapy are used (depending on the situation, antiplatelet agents or anticoagulants may be used in combination or alone).
  • Lifestyle management: Aggressively control cardiovascular risk factors (hypertension, diabetes, hyperlipidemia, etc.), do not smoke, and prevent dehydration.
• Precautions (side effects and monitoring)
  • Hydroxyurea: Bone marrow suppression, skin abnormalities, and long-term side effects (rare) — regular monitoring of blood counts is necessary.
  • Interferon: Fatigue, depression, and flu-like symptoms, particularly with long-term use.
  • JAK inhibitors (ruxolitinib): Monitoring is necessary for infection risk, changes in blood cell counts, weight changes, and metabolic effects.
  • TKIs (CML): Major side effects vary by drug (gastrointestinal symptoms, arrhythmia, liver function abnormalities, etc.) — regular blood and liver function tests are necessary.
  • Situations requiring emergency or immediate medical attention: Acute chest pain, shortness of breath, severe headache, visual disturbances, rapidly progressing bleeding, decreased consciousness, etc. (suspected thrombosis or a cerebrovascular event).

3. Checkpoints Before an Outpatient Visit (Items to Bring and Records)

• Materials/items to bring
  • List of medications and supplements currently being taken (including doses and administration times)
  • Previous test results (recent CBC, peripheral blood smear, bone marrow examination, and genetic test results [JAK2/CALR/MPL/BCR‑ABL])
  • Recent history of bleeding or thrombosis (date of occurrence and treatment received), and transfusion records
  • Symptom records (time of onset, frequency, triggers, aggravating factors), weight changes, and whether fever is present
  • Pregnancy plans or pregnancy status (for women), and breastfeeding status
  • Basic health information: cardiovascular risk factors (hypertension, diabetes, smoking, etc.)
• Tests that may be checked during an outpatient visit (examples)
  • Recent CBC (hemoglobin, white blood cells, and platelets), peripheral blood smear, platelet function testing (if necessary), serum iron/ferritin/erythropoietin, etc.
  • Genetic mutation testing (JAK2/CALR/MPL/BCR‑ABL)
  • Bone marrow examination (evaluation of diagnosis, stage, and degree of fibrosis)
  • Imaging: Abdominal ultrasound (spleen size); cardiovascular or neurological examinations if necessary (when thrombosis is suspected)

4. Examples of General Questions to Ask the Doctor

• "What is the exact disease type (e.g., PV, ET, PMF, or CML), and what does my genetic test result mean?"
• "What treatment targets are recommended (e.g., target hematocrit or platelet count)?"
• "What are the major side effects of the medication (or procedure) you plan to prescribe, and how will they be monitored?"
• "Is this a case where it is acceptable to observe without treatment, and when should active treatment be started?"
• "What is the prognosis, and what should I be careful about in daily life?"

5. Examples of Disease-Specific Questions

• Genetic-related:
  • "Which mutation among JAK2/CALR/MPL/BCR‑ABL was found in my test? How does the recommended treatment differ depending on that mutation?"
• Thrombosis and bleeding-related:
  • "Why do you recommend aspirin for me even though I have no history of thrombosis? When would it be necessary to use an anticoagulant as well?"

(Note: The information above is provided for general informational purposes. Individual diagnosis and treatment plans should be determined through consultation with the hematology specialist in charge.)